Cromolyn sodium.

Cromolyn sodium is a valuable agent in the pharmacologic management of asthma. In addition to its established effects of inhibiting mediator release, it now appears that it is a useful drug for diminishing the effects of reflex-mediated asthma, nonspecific bronchial hyperreactivity, and diurnal swings of bronchial lability. Because of these unique prophylactic properties, the availability of a nebulized aqueous solution delivery system and recent clinical reports showing that its efficacy is comparable to theophylline, cromolyn sodium should be reconsidered as a first-line antiasthmatic drug in the United States.

[1]  S. Godfrey,et al.  Heterogeneity in the response of asthmatic patients to pre-exercise treatment with cromolyn sodium. , 2015, The American review of respiratory disease.

[2]  K. Berkin,et al.  Dose-response study of sodium cromoglycate in exercise-induced asthma. , 1982, Thorax.

[3]  J. Turner,et al.  Comparison of nebulised sodium cromoglycate and oral theophylline in controlling symptoms of chronic asthma in pre-school children: a double blind study. , 1982, Australian and New Zealand journal of medicine.

[4]  T. Orr,et al.  ROLE OF BRONCHIAL IRRITANT RECEPTORS IN ASTHMA , 1981, The Lancet.

[5]  A. O. Hughes,et al.  Controlled trial of cromoglycate and slow-release aminophylline in perennial childhood asthma. , 1980, British medical journal.

[6]  N. Mazurek,et al.  A binding site on mast cells and basophils for the anti-allergic drug cromolyn , 1980, Nature.

[7]  R. Altounyan,et al.  Review of clinical activity and mode of action of sodium cromoglycate , 1980, Clinical allergy.

[8]  E. R. Mcfadden,et al.  Evaluation of role played by mediators of immediate hypersensitivity in exercise-induced asthma. , 1980, The Journal of clinical investigation.

[9]  P. Greengard,et al.  Antiallergic drug cromolyn may inhibit histamine secretion by regulating phosphorylation of a mast cell protein. , 1980, Science.

[10]  A. Wanner.  The role of mucociliary dysfunction in bronchial asthma. , 1979, The American journal of medicine.

[11]  D. E. Klein,et al.  Adverse reactions to cromolyn. , 1979, JAMA.

[12]  B. Zweiman,et al.  Antigen-induced neutrophil chemotactic activity in man. Correlation with bronchospasm and inhibition by disodium cromoglycate. , 1978, The Journal of allergy and clinical immunology.

[13]  D. Cockcroft,et al.  Allergen‐induced increase in non‐allergic bronchial reactivity , 1977, Clinical allergy.

[14]  S. Godfrey,et al.  COMPARISON OF CROMOGLYCATE (CROMOLYN) AND THEOPHYLLINE IN CONTROLLING SYMPTOMS OF CHRONIC ASTHMA A Collaborative Study , 1977, The Lancet.

[15]  R. Townley,et al.  Cromolyn therapy in patients with bronchial asthma. Effect on inhalation challenge with allergen, histamine, and methacholine. , 1976, JAMA.

[16]  I. Bernstein,et al.  A controlled study of cromolyn sodium sponsored by the Drug Committee of the American Academy of Allergy. , 1972, The Journal of allergy and clinical immunology.

[17]  J. Cox,et al.  Disodium Cromoglycate, an Inhibitor of Mast Cell Degranulation and Histamine Release induced by Phospholipase A , 1969, Nature.

[18]  F. Hargreave,et al.  Inhibitory effects of disodium cromoglycate on allergen-inhalation tests. , 1968, Lancet.

[19]  J. Howell,et al.  A double-blind trial of disodium cromoglycate in the treatment of allergic bronchial asthma. , 1967, Lancet.